Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.
[powerpress]
Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
[powerpress]
Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for patients with advanced NSCLC, as well as whether smoking status factors into her approach.
[powerpress]
Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
[powerpress]
As a second part of a recent video I did that introduces the concept of a mixed response in lung cancer (or many other cancers) and how we might manage that situation, I wanted to cover the biology of what is presumably occurring. Here's a video that covers this issue, as well as the implication that we can learn more about this by doing multiple biopsies, more than is considered as the typical standard now.
[powerpress]
One of the current controversies in the field of lung cancer is whether we should be doing biopsies routinely when a patient develops progression of their disease, particularly in the setting of acquired resistance to a molecularly targeted therapy. There are some academic oncologists who favor this approach, but I think there's a very good reason why this isn't and shouldn't be the current standard of care.
[powerpress]
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock
